Component: (Network and Table)
Network
00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS
(http://www.inva.com/role/StatementConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001080014 (http://www.sec.gov/CIK)
CONSOLIDATED STATEMENTS OF CASH FLOWSPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
 
 
Cash flows from operating activities
 
 
 
Net income (loss)
59,536,000  
(18,760,000) 
(168,464,000) 
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
13,954,000  
13,933,000  
12,175,000  
Stock-based compensation
8,297,000  
6,873,000  
27,390,000  
Amortization of premium (discount) on short term investment
(9,000) 
583,000  
1,742,000  
Interest added to the principal balance of the non-recourse term notes due 2029
855,000  
22,635,000  
20,527,000  
Gain on repurchase of convertible subordinated notes due 2023
(2,342,000) 
0  
0  
Amortization of debt issuance costs
2,847,000  
2,943,000  
2,408,000  
Other-than-temporary impairment loss on marketable securities
0  
0  
3,752,000  
Realized gain on sale of marketable securities, net
0  
(1,220,000) 
0  
Amortization of lease guarantee
(190,000) 
0  
0  
Other non-cash items
0  
(3,000) 
(2,000) 
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
0  
0  
74,000  
Receivables from collaborative arrangements
(20,619,000) 
(15,678,000) 
(7,371,000) 
Prepaid expenses and other current assets
48,000  
320,000  
(338,000) 
Inventories
0  
0  
(1,908,000) 
Other assets
(19,000) 
0  
1,549,000  
Accounts payable
(690,000) 
818,000  
(7,695,000) 
Payable to Theravance Biopharma, Inc., net
0  
(1,056,000) 
(15,916,000) 
Accrued personnel-related expenses and other accrued liabilities
276,000  
(725,000) 
(491,000) 
Accrued interest payable
(83,000) 
360,000  
4,751,000  
Other long-term liabilities
8,000  
(7,000) 
275,000  
Deferred revenue
(885,000) 
(885,000) 
(3,181,000) 
Net cash provided by (used in) operating activities
60,984,000  
 
10,131,000  
 
(130,723,000) 
 
Cash flows from investing activities
 
 
 
Maturities of marketable securities
88,422,000  
137,621,000  
339,359,000  
Purchases of marketable securities
(95,719,000) 
(86,523,000) 
(276,914,000) 
Sales of marketable securities
2,995,000  
108,077,000  
7,211,000  
Purchases of property and equipment
(278,000) 
(7,000) 
(689,000) 
Capitalized fees paid to a related party
0  
0  
(135,000,000) 
Change in restricted cash
0  
0  
833,000  
Payments received on notes receivable
0  
0  
140,000  
Net cash (used in) provided by investing activities
(4,580,000) 
 
159,168,000  
 
(65,060,000) 
 
Cash flows from financing activities
 
 
 
Repurchase of common stock
(78,094,000) 
(25,636,000) 
0  
Repurchase of convertible subordinated notes due 2023
(11,570,000) 
0  
0  
Payment of principal on non-recourse notes due 2029
(6,828,000) 
0  
0  
Payments of cash dividends to stockholders
(960,000) 
(87,331,000) 
(56,988,000) 
Repurchase of shares to satisfy tax withholding
(1,079,000) 
(2,192,000) 
(5,664,000) 
Proceeds from capped-call options
578,000  
0  
0  
Cash and cash equivalents contributed to Theravance Biopharma, Inc.
0  
0  
(277,541,000) 
Proceeds from issuance of notes payable, net of debt issuance costs
0  
0  
434,677,000  
Proceeds from issuances of common stock, net
385,000  
8,240,000  
54,589,000  
Net cash (used in) provided by financing activities
(97,568,000) 
 
(106,919,000) 
 
149,073,000  
 
Net (decrease) increase in cash and cash equivalents
(41,164,000) 
 
62,380,000  
 
(46,710,000) 
 
Cash and cash equivalents at beginning of period
159,180,000  
96,800,000  
143,510,000  
Cash and cash equivalents at end of period
118,016,000  
 
159,180,000  
 
96,800,000  
 
Supplemental disclosure of cash flow information
 
 
 
Cash paid for interest
48,797,000  
25,863,000  
9,208,000  
Supplemental disclosure of noncash information
 
 
 
Contribution of net assets, excluding cash and cash equivalents to Theravance Biopharma, Inc.
0  
0  
125,337,000  
Conversion of convertible subordinated notes to common stock
0  
0  
32,391,000